Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiac Catheterization II: Right Heart Catheterization

Cardiac Catheterization II: Right Heart Catheterization

Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Imbalances in Cardiac Output

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An attention-infused deep convolutional paradigm for multi-label classification of thoracic pathologies in chest radiographs.

Scientific reports·2026

Same author

Correction: Sensitivity-informed framework for enrichment distribution in MNR for thermal performance enhancement.

Scientific reports·2026

Same author

A district-based health facility assessment for maternal and newborn care across Pakistan.

Journal of global health·2026

Same author

Oxygen-vacancy-mediated silver release from mesoporous CeO<sub>2</sub> for durable antimicrobial coatings.

Journal of colloid and interface science·2026

Same author

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Vaccine·2026

Same author

Sensitivity-informed framework for enrichment distribution in MNR for thermal performance enhancement.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Cardiac complications after stem cell transplantation.

Tariq Mahmood Satti¹, Khalil Ullah, Pervez Ahmed

¹Department of Haematology, AFBMTC, Rawalpindi.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

|August 10, 2007

Summary

Intensive chemotherapy, including cyclophosphamide and busulphan, can cause severe cardiac complications in stem cell transplant patients. This study reports two cases of life-threatening heart issues requiring surgical intervention.

More Related Videos

Intramyocardial Cell Delivery: Observations in Murine Hearts

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Related Experiment Videos

Last Updated: Jul 13, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Intramyocardial Cell Delivery: Observations in Murine Hearts

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Area of Science:

Cardiology
Hematology
Oncology

Background:

Cardiac toxicity is a known complication of intensive cytotoxic therapy in stem cell transplantation.
Clinically significant cardiac toxicity occurs in 2-43% of patients, with mortality rates of 2-9%.

Purpose of the Study:

To report two cases of life-threatening cardiac complications following cyclophosphamide and busulphan therapy in stem cell transplant recipients.

Main Methods:

Review of two patient cases with severe cardiac events post-chemotherapy.
Documentation of treatment interventions, including pericardiocentesis and pericardiectomy.

Main Results:

Two patients developed severe cardiac insufficiency/toxicity after cyclophosphamide and busulphan treatment.
Both patients required invasive procedures (pericardiocentesis and pericardiectomy) to manage life-threatening cardiac complications.

Conclusions:

Cyclophosphamide and busulphan therapy can lead to severe, life-threatening cardiac complications in stem cell transplant patients.
Prompt recognition and intervention are crucial for managing these adverse cardiac events.